ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

To evaluate the safety of different doses of IMC-002 in the treatment of patients with neuromyelitis optica spectrum disorders, and determine the optimal therapeutic dose of IMC-002 together with the Phase Ib clinical trial of IMC-002 in the treatment of SLE To evaluate the time to first clinical relapse at or within 52 weeks of IMC-002 compared with active control drugs in patients with neuromyelitis optica spectrum disorders